Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.56 |
| ▸ | NOS1 | P29475 | 4/20 | 0.56 |
| ▸ | NOS3 | P29474 | 2/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 7/20 | 0.47 |
| ▸ | ATF1 | P18846 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064365 | 0.88 | NOS3 (0.54) | NOS2NOS1NOS3PDK1ATF1 | |
| SCHEMBL3056338 | 0.87 | NOS3 (0.53) | NOS2NOS1NOS3PDK1ATF1 | |
| SCHEMBL3050573 | 0.86 | NOS3 (0.52) | NOS2NOS1NOS3PDK1ATF1 | |
| SCHEMBL3061190 | 0.86 | NOS2 (0.54) | NOS2NOS1NOS3PDK1ATF1 | |
| SCHEMBL3054013 | 0.86 | NOS1 (0.51) | NOS2NOS1NOS3PDK1ATF1 | |
| SCHEMBL3044228 | 0.85 | NOS3 (0.51) | NOS2NOS1NOS3PDK1ATF1 | |
| SCHEMBL3058776 | 0.84 | NOS2 (0.53) | NOS2NOS1NOS3PDK1ATF1 | |
| SCHEMBL3052528 | 0.84 | NOS1 (0.49) | NOS2NOS1NOS3PDK1ATF1 | |
| SCHEMBL3043358 | 0.84 | NOS2 (0.56) | NOS2NOS1NOS3PDK1ATF1 | |
| SCHEMBL3053769 | 0.84 | NOS3 (0.49) | NOS2NOS1NOS3PDK1ATF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | NOS2 3548/4885NOS1 3682/4885NOS3 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.